BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ho CM, Lee CH, Lee MC, Zhang JF, Wang JY, Hu RH, Lee PH. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study. BMC Cancer. 2018;18:401. [PMID: 29631561 DOI: 10.1186/s12885-018-4292-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Li X, Wu S, Yu Y. Aspirin Use and the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B Virus or Hepatitis C Virus Infection: A Meta-Analysis of Cohort Studies. Front Med (Lausanne) 2020;7:569759. [PMID: 33490093 DOI: 10.3389/fmed.2020.569759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Yi M, Feng X, Peng W, Teng F, Tang Y, Chen Z. Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis with particular focus on patients with chronic liver disease. Eur J Clin Pharmacol 2022. [PMID: 35032181 DOI: 10.1007/s00228-021-03247-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Masior Ł, Grąt M. Exploring new pathways in the treatment of hepatocellular cancer. Ann Transl Med 2020;8:980. [PMID: 32953780 DOI: 10.21037/atm-20-3629] [Reference Citation Analysis]
4 Lopez-Lopez V, Gomez Ruiz A, Lopez-Conesa A, Brusadin R, Cayuela V, Caballero-Illanes A, Torres M, Robles Campos R. Effects of primary hypertension treatment in the oncological outcomes of hepatocellular carcinoma. Ann Transl Med 2020;8:844. [PMID: 32793688 DOI: 10.21037/atm.2020.04.40] [Reference Citation Analysis]
5 Ziaja M, Urbanek KA, Kowalska K, Piastowska-Ciesielska AW. Angiotensin II and Angiotensin Receptors 1 and 2-Multifunctional System in Cells Biology, What Do We Know? Cells 2021;10:381. [PMID: 33673178 DOI: 10.3390/cells10020381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Sanidas E, Velliou M, Papadopoulos D, Fotsali A, Iliopoulos D, Mantzourani M, Toutouzas K, Barbetseas J. Antihypertensive Drugs and Risk of Cancer: Between Scylla and Charybdis. Am J Hypertens 2020;33:1049-58. [PMID: 32529212 DOI: 10.1093/ajh/hpaa098] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
7 Barone M, Viggiani MT, Losurdo G, Principi M, Leo AD. Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma. World J Gastroenterol 2019; 25(20): 2524-2538 [PMID: 31171895 DOI: 10.3748/wjg.v25.i20.2524] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
8 Zhang X, Wong GL, Yip TC, Tse YK, Liang LY, Hui VW, Lin H, Li GL, Lai JC, Chan HL, Wong VW. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. Hepatology 2021. [PMID: 34939204 DOI: 10.1002/hep.32294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Liao YH, Hsu RJ, Wang TH, Wu CT, Huang SY, Hsu CY, Su YC, Hsu WL, Liu DW. Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study. BMC Gastroenterol 2020;20:6. [PMID: 31918672 DOI: 10.1186/s12876-020-1158-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Zhang M, Chen X, Radacsi N. New tricks of old drugs: Repurposing non-chemo drugs and dietary phytochemicals as adjuvants in anti-tumor therapies. J Control Release 2021;329:96-120. [PMID: 33259852 DOI: 10.1016/j.jconrel.2020.11.047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
11 Chen CY, Wang TY, Chen WM, Chen KH, Yang YH, Chen PC, Chen VC. Bilateral oophorectomy and the risk of hepatocellular carcinoma in women with hepatitis C: A population-based study. Maturitas 2021;146:11-7. [PMID: 33722359 DOI: 10.1016/j.maturitas.2020.12.006] [Reference Citation Analysis]
12 Regulska K, Regulski M, Karolak B, Michalak M, Murias M, Stanisz B. Beyond the boundaries of cardiology: Still untapped anticancer properties of the cardiovascular system-related drugs. Pharmacological Research 2019;147:104326. [DOI: 10.1016/j.phrs.2019.104326] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, Yoshiji H, Yatsuhashi H, Shimizu M, Torimura T, Moriyama M, Sakaida I, Okada H, Chiba T, Chuma M, Nakao K, Isomoto H, Sasaki Y, Kaneko S, Masaki T, Chayama K, Koike K. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update. J Gastroenterol 2019;54:367-76. [PMID: 30498904 DOI: 10.1007/s00535-018-1532-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 14.5] [Reference Citation Analysis]
14 Regulska K, Regulski M, Karolak B, Murias M, Stanisz B. Can cardiovascular drugs support cancer treatment? The rationale for drug repurposing. Drug Discovery Today 2019;24:1059-65. [DOI: 10.1016/j.drudis.2019.03.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
15 Kusnik A, Hunter N, Rasbach E, Miethke T, Reissfelder C, Ebert MP, Teufel A. Co-Medication and Nutrition in Hepatocellular Carcinoma: Potentially Preventative Strategies in Hepatocellular Carcinoma. Dig Dis 2021;39:526-33. [PMID: 33429390 DOI: 10.1159/000514277] [Reference Citation Analysis]